In Table 1, we have summarized eight USFDA-approved small molecules for the AD to date to have an overview. Table 1. List of USFDA approved small molecules for the treatment of AD. Brand nameDrugDrug Target & MOADosingAdverse EffectsWebsite Adbry Tralokinumab-ldrm IL-13 Inhibitor: ...
Dupilumab was the first new systemic therapy to receive approval for the treatment of moderate-to-severe AD [4]. However, more than 60% of patients in dupilumab phase 3 randomized controlled trials did not achieve pre-established efficacy endpoints [5] and up to approximately 30% of ...
“In multiple large-scale clinical trials, CIBINQO demonstrated strong efficacy at clearing skin, improving itch, and managing the extent and severity of eczema, offering a benefit-risk profile that supports the use of this treatment in the FDA-approved patient population.” The FDA ...
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. Ann. Pharm. 2023, 57, 86–98. [Google Scholar] [CrossRef] [PubMed] Elmariah, S.B.; Smith, J.S.; Merola, J.F. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. Am....